First adaptive platform trial in ALS could speed development, find new biomarkers

An adaptive platform trial for ALS launched by Mass General could find new biomarkers to serve as surrogate endpoints or predictors of response in the pivotal trial and future studies.

Researchers at Massachusetts General Hospital’s Sean M. Healey & AMG Center for ALS believe the time is ripe for the first ever platform trial in amyotrophic lateral sclerosis given the increased understanding of the disease's underlying biology and the more than 100 companies with candidates in preclinical or clinical development for the disease...